Relapse and prognostic factors after anti-thyroid therapy for Graves-Basedow disease. Multicentric study in Northern Spain;Recidiva y factores pronósticos tras tratamiento con antitiroideos en la enfermedad de Graves-Basedow. Estudio multicéntrico en el norte de España

Revista Clinica Espanola

Volumn 200, Issue 2, 2000, Pages 69-73

  Menendez Torre E ^a   Anda Apinaniz E ^a   Barberia Layana J J ^a   Valdes Gallego N ^b   Rabal Artal, A ^b   Diaz Cadorniga F ^b   Santamaria Sandi J ^c   Vazquez Garcia J A ^c  

^a Universidad Pública de Navarra   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

Author keywords

Anti thyroid drugs; Graves Basedow disease; Hyperthyroidism

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; PROPYLTHIOURACIL; THIAMAZOLE; THYROID ANTIBODY; THYROID HORMONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; FEMALE; GRAVES DISEASE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; RECURRENT DISEASE; SPAIN; FOLLOW UP; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; RELAPSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHYROID AGENTS; CARBIMAZOLE; CHILD; FEMALE; GRAVES DISEASE; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED; PROGNOSIS; PROPYLTHIOURACIL; RECURRENCE; SPAIN;

EID: 0034136036     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0014-2565(00)70566-2     Document Type: Article

References (49)

1. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham Survey. Clin Endocrinol Oxf 1977; 7: 481-493.
2. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J. Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh) 1986; 111:39-43.
3. Yamada T, Aizawa T, Koizumi Y, et al. Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves' disease. J Am Geriatr Soc 1994; 42:513-516.
4. Allannic H, Fauchet R, Lorcy Y, et al. A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype. J Clin Endocrinol Metab 1983; 57:719-722.
5. Schleusener H, Schwander J, Holl G, et al. Do HLA-DR typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment? Acta Endocrinol (Copenh) 1987; 115 (suppl 281):318-324.
6. Eshoj O, Kvetny J, Mogensen EF, Bech K, Bliddal H. Prediction of the course of Graves' disease after medical antithyroid treatment. Acta Med Scand 1985; 217:225-228.
7. Allannic H, Fauchet R, Orgizzi J, et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70:675-679.
8. Romaldini JH, Bromberg N, Werner RS, et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57:563-570.
9. Reinwein D, Benker G, Lazarus JH, Alexander WD, and the European Multicentre Study Group on Antithyroid Drug Treatment. A prospective randomized trial of antithyroid drug dose in Grave's disease therapy. J Clin Endocrinol Metab 1993; 76:1.516-1.521.
10. García-Mayor RV, Páramo C, Luna R, et al. Antithyroid drug and Graves' hyperthyroidism. Significance treatment duration and TRAb determination of lasting remission. J Endocrinol Invest 1992; 15:815-820.
11. Grebe SK, Feek CM, Ford HC, et al. A randomized trial of short-term treatment of Grave's disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol Oxf 1998; 48:585-592.
12. Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves' disease. Effects of the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324:947-953.
13. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334:220-224.
14. Hamada N, Ito K, Mimura T, et al. Retrospective reevaluation of the significance of thyroid microsomal antibody in the treatment of Graves' disease. Acta Endocrinol (Copenh) 1987; 114:328-335.
15. Aizawa T, Ishihara M, Koizumi Y, et al. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy. Am J Med 1990; 89:175-180.
16. Wenzel KW, Lente JR. Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves' disease. J Endocrinol Invest 1983; 6:389-394.
17. Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD. Scottish Automated Follow-Up Register Group. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Clinical Endocrinology 1989; 31:209-218.
18. Dahlberg PA, Karlsson FA, Jansson R, Wide L. Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission. J Clin Endocrinol Metab 1985; 61:1 100-1.104.
19. Benker G, Reinwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves' disease? The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Results from a long-term prospective study. Clin Endocrinol Oxf 1998; 49: 451-457.
20. Glinoer D, Hesh D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol (Copenh) 1987; 115 (suppl 285):3-23.
21. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan and the United States. Thyroid 1991; 1:129-135.
22. Escobar F, Luna V, Fernández ML, Quesada M, Glinoer D. Evolución de los criterios diagnósticos y terapéuticos en la enfermedad de Graves en España. Comparación de los resultados de dos encuestas realizadas en 1987 y 1995. Med Clín (Barc) 1998; 111:205-210.
23. Delange F, Bastani S, Benmiloud M, et al. Definitions of endemic gloiter and cretinism, classification of goiter size and severity of endemias and survey techniques. En: Dunn et al, eds. Towards the erradication of endemic goiter, cretinism and iodine deficiency. Washington: Pan American Health Organization, 1986: 373-376.
24. Winsa B, Dahlberg A, Jansson R, Agren H, Karlsson FA. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol (Copenh) 1990; 122:722-728.
25. Solomon BL, Evaul JE, Burman KD, Wartofsky L. Remission rates with antithyroid drug therapy: cointinuing influence of iodine intake? Ann Intern Med 1987; 107:510-512.
26. Wartofsky L. Low remission after therapy for Graves' disease: possible relation of dietary iodine with antithyroid therapy results. JAMA 1973; 226:1.083-1.088.
27. Menéndez Torre E, Aranda Regules J, Díaz Cadórniga FJ, Boix Pallarés P, Aller Granda J, Rabal Artal A. Estudio epidemiológico del bocio endémico en la población infantil asturiana. Endocrinología 1986; 33 (suppl 1): 16-20.
28. Goñi F, Barbería JJ, Olega A, Escobar H, Yoldi A, Moncada E, Escobar del Rey F. Alteraciones por deficiencia de yodo y bocio endémico en los escolares de Navarra. Endocrinología 1993; 40:267-272.
29. Delgado E, Díaz-Cadórniga FJ, Boix P, et al. Bocio endémico en la población infantil escolar de Asturias tras 10 años de profilaxis con sal yodada. Endocrinología 1994; 41 (suppl 3):43.
30. Schleusener H, Schwander J, Ficher C, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 1989; 120:689-701.
31. Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Grave's disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7:369-375.
32. Young ET, Steel NR, Taylor JJ, et al. Prediction of remission after antithyroid drug treatment in Graves' disease. Q J Med 1988; 250:175-189.
33. Bouma DJ, Kammer H, Greer MA. Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease. J Clin Endocrinol Metab 1982; 55:1.138-1.142.
34. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 1994; 78:98-102.
35. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Coman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Grave's disease with antithyroid drugs. Thyroid 1998; 8:119-124.
36. Wilson R, McKillop JH, Thomson JA. The prognostic value of thyrotropin receptor antibody (TRAb) levels in Graves' disease. Ann Clin Biochem 1990; 27:601-602.
37. Wilson R, McKillop JH, Henderson N, Pearson DW, Thomson JA. The ability of the serum thyrotropin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease. Clin Endocrinol (Oxf) 1986; 25:151-156.
38. Docter R, Bos G, Visser TJ, Hennemann G. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy and its relation to long acting thyroid stimulator. Clin Endocrinol (Oxf) 1980; 12:143-153.
39. Murakami M, Koizumi Y, Aizawa T, et al. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission. J Clin Endocrinol Metab 1988; 66:103-108.
40. McGregor AM, Smith BR, Hall R, Petersen MM, Miller M, Dewar PJ. Prediction of relapse in hyperthyroid Graves' disease. Lancet 1980; 1:1.101-1.103.
41. Takata I, Suzuki Y, Saida K, Sato T. Human thyroid stimulating activity and clinical state in antithyroid treatment of juvenile Graves' disease. Acta Endocrinol (Copenh) 1980; 94:46-52.
42. Zakarija M, McKenzie JM, Banovac K. Clinical significance of assay of thyroid-stimulating antibody in Graves' disease. Ann Intern Med 1980; 93:28-32.
43. [2]I therapy given in combination with carbimazole and in euthyroid ophthalmopathy. Acta Endocrinol (Copenh) 1981; 98:364-369.
44. Teng CS, Yeung RT. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drugs and its relationship to relapse: a prospective study. J Clin Endocrinol Metab 1980; 50:144-147.
45. De Bruin TWA, Bolk JH, Bussemaker JH, et al. Graves' disease: immunological and immunogenetic indicators of relapse. Br Med J 1988; 296:1.292-1.295.
46. Madec AM, Laurent MC, Lorcy Y, et al. Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves' disease? Clin Endocrinol (Oxf) 1984; 21:247-255.
47. Allannic H, Lorcy Y, Leguerrier AM, et al. Antithyroidiens de synthese et maladie de Basedow ou le choix d'une strategie therapeutique. Presse Med 1991; 20:645-651.
48. Weetman AP, Ratanachaiyavong S, Middleton GW, et al. Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med 1986; 59:409-419.
49. Tamai H, Nakagawa T, Fukino O, et al. Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy. Ann Intern Med 1980; 92:488-490.